Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Carcinoma of the Eyelid Clinical TNM Finding v7	NCIT_C88575	[A clinical finding about one or more characteristics of carcinoma of the eyelid, following the rules of the TNM AJCC v7 classification system. Staging of eyelid carcinoma begins with a comprehensive ophthalmic, orbital, and periorbital clinical examination. This approach includes a slit lamp or equivalent biomicroscopy evaluation, neuro-ophthalmic examination for evidence of perineural invasion, and regional assessment of the head and neck including lymphatic drainage basins. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid cNX TNM Finding v7	NCIT_C88577	[Carcinoma of the eyelid in which the regional lymph nodes cannot be assessed. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid cN0 TNM Finding v7	NCIT_C88578	[Carcinoma of the eyelid with no regional lymph node metastasis, based upon clinical evaluation or imaging. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid cN1 TNM Finding v7	NCIT_C88579	[Carcinoma of the eyelid with regional lymph node metastasis. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid cM1 TNM Finding v7	NCIT_C88583	[Carcinoma of the eyelid with distant metastasis. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid Clinical Distant Metastasis TNM Finding v7	NCIT_C88581	[A clinical finding about one or more characteristics of carcinoma of the eyelid, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.]
Motavizumab	NCIT_C88584	[A humanized monoclonal antibody directed against the respiratory syncytial virus (RSV) fusion glycoprotein (F-protein), with activity against RSV. Motavizumab targets and binds to the RSV F-protein, which prevents F-protein-mediated RSV fusion with human host cells. This protects against RSV infection. RSV F-protein mediates RSV attachment and fusion to host cells.]
Solanezumab	NCIT_C88585	[A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Solanezumab recognizes and binds the middle amino acid residues 16-24 of the amyloid beta peptide and may be used in a passive immunotherapy treatment.]
Carcinoma of the Conjunctiva TNM Finding v7	NCIT_C88586	[A finding about one or more characteristics of carcinoma of the conjunctiva, following the rules of the TNM AJCC v7 classification system. No stage grouping is presently recommended for carcinoma of the conjunctiva. (from AJCC 7th Ed.)]
Ophthalmic Sites Cancer TNM Finding v7	NCIT_C88556	[A finding about one or more characteristics of ophthalmic sites cancer, following the rules of the TNM AJCC v7 classification system.]
Gantenerumab	NCIT_C88580	[A monoclonal antibody against beta-amyloid (Abeta40/42) used in the treatment of Alzheimer's disease. Gantenerumab targets and binds to beta amyloid then is removed through effector cell-mediated clearance. This reduces the level of beta amyloid in the brain. In Alzheimer's disease, beta amyloid accumulates in the brain and is a key component in plaque formation.]
Carcinoma of the Eyelid cM0 TNM Finding v7	NCIT_C88582	[Carcinoma of the eyelid without evidence of distant metastasis. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid Pathologic Regional Lymph Nodes TNM Finding v7	NCIT_C88569	[A pathologic finding about one or more characteristics of carcinoma of the eyelid, following the rules of the TNM AJCC v7 classification system as they pertain to staging of regional lymph nodes.]
Carcinoma of the Eyelid Pathologic TNM Finding v7	NCIT_C88558	[A pathologic finding about one or more characteristics of carcinoma of the eyelid, following the rules of the TNM AJCC v7 classification system. The surgical nature of the histopathology specimen should be noted including incisional biopsy, excisional biopsy, wide local excision, radical excision including exenteration. The specimen should be carefully oriented and inked for margin evaluation. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid pT2b TNM Finding v7	NCIT_C88565	[Carcinoma of the eyelid with tumor measuring more than 10 mm, but not more than 20 mm in greatest dimension. Or, tumor involving the full thickness of eyelid. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid Pathologic Primary Tumor TNM Finding v7	NCIT_C88559	[A pathologic finding about one or more characteristics of carcinoma of the eyelid, following the rules of the TNM AJCC v7 classification system as they pertain to staging of the primary tumor.]
Carcinoma of the Eyelid pT3a TNM Finding v7	NCIT_C88566	[Carcinoma of the eyelid with tumor measuring more than 20 mm in greatest dimension. Or, any tumor invading adjacent ocular or orbital structures. Or, any T with perineural tumor invasion. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid pT3b TNM Finding v7	NCIT_C88567	[Carcinoma of the eyelid for which complete tumor resection requires enucleation, exenteration, or bone resection. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid pT4 TNM Finding v7	NCIT_C88568	[Unresectable carcinoma of the eyelid due to extensive invasion of ocular, orbital, and craniofacial structures, or brain. (from AJCC 7th Ed.)]
Carcinoma of the Eyelid pN1 TNM Finding v7	NCIT_C88572	[Carcinoma of the eyelid with regional lymph node metastasis. (from AJCC 7th Ed.)]